Flotillin-2: A new potential predictor for prognosis of breast cancer
Overexpression of ErbB2 occurs in up to 30% of human breast cancers. ErbB2 is not down-regulated by ligand-induced mechanisms as many other receptors. In a new study now published in Oncogene (journal impact factor 6.4), Sascha Pust (photo) from Kirsten Sandvig's group at the Institute for Cancer Research and coworkers show that flotillins stabilize ErbB2 at the plasma membrane. Moreover, microarray analysis of biopsies of 194 breast cancer patients indicated that flotillin-2 is a good prognostic marker for breast cancer. Depletion of flotillins leads to internalization and degradation of ErbB2, thereby inhibiting the ErbB2-triggered signaling.
This study was a collaboration between several groups, including three groups (Sandvig, Danielsen, Liestøl) from the Center for Cancer Biomedicine (CCB).
Chauhan SK, Dunn C, Andresen NK, Røssevold AH, Skorstad G, Sike A, Gilje B, Raj SX, Huse K, Naume B, Kyte JA(2024) Peripheral immune cells in metastatic breast cancer patients display a systemic immunosuppressed signature consistent with chronic inflammation NPJ Breast Cancer, 10(1), 30 DOI 10.1038/s41523-024-00638-2, PubMed 38653982
Miceli R, Eriksson H, Lo Russo G, Alfieri S, Moksnes Bjaanæs M, Pietrantonio F, De Cecco L, Prelaj A, Proto C, Franzén J, McDonnell D, Berenguer Pina JJ, Beninato T, Mazzeo L, Giannatempo P, Verzoni E, Crown J, Helland Å, Eustace A(2024) Gender Difference in sidE eFfects of ImmuNotherapy: a possible clue to optimize cancEr tReatment (G-DEFINER): study protocol of an observational prospective multicenter study Acta Oncol, 63, 213-219 DOI 10.2340/1651-226X.2024.24179, PubMed 38647024
Fackler MJ, Pleas M, Li Y, Soni A, Xing D, Cope L, Ali S, Van Le Q, Van Nguyen C, Pham HT, Duong LM, Vanden Berg E, Wadee R, Michelow P, Chen WC, Joffe M, Fjeldbo CS, Lyng H, Sukumar S(2024) Discovery and technical validation of high-performance methylated DNA markers for the detection of cervical lesions at risk of malignant progression in low- and middle-income countries Clin Epigenetics, 16(1), 56 DOI 10.1186/s13148-024-01669-z, PubMed 38643219